MDS with Isolated del(5q)
A distinct, often lower-risk myelodysplastic syndrome marked by macrocytic anemia and a single chromosome 5q deletion, frequently responsive to targeted therapy.
- Lenalidomide-responsive subtype
- Generally favorable risk profile
- Specialist molecular work-up available
- Most Common In
- Older adults, more often women
- Defining Feature
- Isolated deletion of chromosome 5q
- Typical Course
- Indolent, often lower-risk
- Advanced Therapies
- Lenalidomide, hypomethylating agents
Condition Overview
MDS with isolated del(5q) is a myelodysplastic syndrome defined by the World Health Organization classification as having a deletion involving the long arm of chromosome 5 as the sole, or near-sole, cytogenetic abnormality. It typically presents with macrocytic anemia, often with a normal or elevated platelet count, distinguishing it clinically from many other MDS subtypes.
The condition tends to affect older adults and is more common in women. Recognition of this subtype matters because it carries a generally favorable prognosis and responds distinctively to a specific targeted therapy, making accurate cytogenetic diagnosis essential before treatment decisions are made.
Types and Subtypes
MDS with isolated del(5q) is itself a defined subtype within the broader myelodysplastic syndrome classification. Variability within this subtype mainly concerns the presence or absence of additional mutations, such as TP53, which can affect prognosis.
Symptoms and Signs
Symptoms in MDS with isolated del(5q) usually stem from anemia and develop gradually, often being noticed only after months of fatigue.
Causes and Risk Factors
The exact trigger for the chromosome 5 deletion is not fully understood, but certain exposures and patient factors are associated with increased risk of developing MDS generally, including this subtype.
Diagnosis and Investigations
Diagnosing MDS with isolated del(5q) requires confirming both the dysplastic blood picture and the specific cytogenetic finding.
Staging and Risk Groups
Risk stratification in MDS relies on the IPSS-R and IPSS-M scoring systems, which incorporate blast percentage, cytogenetics, cytopenias, and molecular findings.
Standard Treatment
Treatment is guided by symptom burden, transfusion dependence, and risk category, with lenalidomide playing a distinctive role in this subtype.
Advanced & Emerging Therapies
Beyond standard lenalidomide and hypomethylating therapy, several emerging approaches are under active investigation for del(5q) MDS, particularly for TP53-mutant or treatment-refractory cases.
Targeted
Next-generation immunomodulatory agents
Newer agents in the lenalidomide class are being studied to extend response duration and address resistance.
Cellular Therapy
Allogeneic stem cell transplantation
Remains the only potentially curative option for eligible higher-risk or TP53-mutant patients.
Precision Medicine
TP53-targeted investigational agents
Novel compounds targeting mutant TP53 biology are being explored in clinical trials for high-risk MDS.
Biomarkers & Precision Medicine
Cytogenetic and molecular testing guide both prognosis and therapy selection in this subtype.
When to Seek 2nd Opinion
Because treatment response and risk vary meaningfully within this subtype, a specialist second opinion can clarify the right path forward.
Clinical Trials & Research
Prognosis & Outcomes
Outcomes in MDS with isolated del(5q) are generally favorable compared with many other MDS subtypes, particularly when TP53 is not mutated.
Supportive Care
Supportive measures help manage symptoms and quality of life throughout the course of this condition.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with del(5q) MDS get expert review of cytogenetic and bone marrow reports, coordinates second opinions, and connects patients with specialists experienced in lenalidomide and transplant decision-making.
Get a free case reviewFrequently Asked Questions
It is a distinct myelodysplastic syndrome subtype defined by a deletion in chromosome 5q as the sole or near-sole cytogenetic abnormality, typically presenting with macrocytic anemia.
It is generally considered a chronic condition managed with therapy, though allogeneic stem cell transplant can offer a potentially curative option for eligible higher-risk patients.
Lenalidomide has a targeted effect on cells carrying the 5q deletion, often producing transfusion independence and cytogenetic responses not typically seen in other MDS subtypes.
A concurrent TP53 mutation is associated with a less favorable course and reduced response to lenalidomide, often prompting earlier consideration of transplant.
Diagnosis requires bone marrow examination, cytogenetic analysis or FISH to confirm the 5q deletion, and molecular sequencing to rule out additional risk-modifying mutations.
Progression is possible but generally less frequent than in higher-risk MDS subtypes, particularly when TP53 is not mutated.
Response is tracked through regular blood counts, transfusion requirements, and periodic bone marrow and cytogenetic reassessment.
It is not typically hereditary; it arises from an acquired chromosomal change in blood-forming cells rather than an inherited gene defect.
Pacing activity, maintaining good nutrition, and prompt attention to infection symptoms can help patients manage fatigue and reduce complications.
Yes. CancerFax helps patients with del(5q) MDS obtain expert medical report review, coordinate second opinions, and connect with specialists experienced in lenalidomide therapy, transplant decision-making, and international care coordination where needed.
Get Expert Guidance for MDS with Isolated del(5q)
Send your bone marrow and cytogenetic reports for specialist review and explore your treatment options with confidence.